Equities researchers at HC Wainwright began coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) in a research note issued on Wednesday, Briefing.com reports. The brokerage set a “neutral” rating and a $8.00 price target on the stock. HC Wainwright’s price target would suggest a potential downside of 0.62% from the stock’s previous close.
Kyverna Therapeutics Trading Up 3.1 %
Shares of NASDAQ KYTX opened at $8.05 on Wednesday. Kyverna Therapeutics has a fifty-two week low of $6.75 and a fifty-two week high of $35.06. The firm has a 50 day simple moving average of $12.52.
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.28). During the same quarter in the prior year, the business earned ($12.10) earnings per share. Research analysts predict that Kyverna Therapeutics will post -3.6 EPS for the current fiscal year.
Institutional Inflows and Outflows
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Read More
- Five stocks we like better than Kyverna Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- Generac Holdings Stock: Mixed Signals Leave Investors Uncertain
- Using the MarketBeat Dividend Yield Calculator
- Analysts and Earnings Propel the S&P 500’s Continuous Growth
- Why is the Ex-Dividend Date Significant to Investors?
- CrowdStrike Stock Soars, Outpacing Palo Alto in Cybersecurity
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.